[시장보고서]류마티스 관절염 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2033년)

류마티스 관절염 치료 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2033년)

Rheumatoid Arthritis Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

상품코드 : 1492319

리서치사 : Persistence Market Research

발행일 : 2024년 05월

페이지 정보 : 영문 295 Pages

라이선스 & 가격 (부가세 별도)

US $ 4,995

￦ 7,282,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295

￦ 10,636,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495

￦ 12,385,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

Persistence Market Research는 세계의 류마티스 관절염(RA) 치료 시장을 상세 분석하고 시장 역학, 성장 촉진요인·과제, 새로운 동향을 강조하고 있습니다. 2024-2033년의 시장 구도를 탐색하기 위한 종합적 데이터와 인사이트를 제공하고, 이해관계자에게 귀중한 리소스입니다.

세계의 류마티스 관절염 치료 시장은 2024-2033년 크게 성장하며, 이 기간의 CAGR은 5.8%로 예측됩니다. 이 시장은 2024년 475억 달러에서 2033년말에는 791억 달러로 증가할 것으로 추정됩니다.

주요 인사이트

추정 시장 가치(2024년) : 475억 달러
예측 시장 가격(2033년) : 791억 달러
세계 시장 성장률(CAGR 2024-2033년) : 5.8%

류마티스 관절염 치료 시장 : 조사 범위

류마티스 관절염은 관절에 영향을 미치는 만성 염증성 질환으로 통증과 부종, 관절의 변형을 유발할 수 있습니다. 류마티스 관절염의 유병률 증가, 인지도 향상, 치료법 발전이 시장을 주도하고 있습니다. 생물학적 제제, 질병 조절 항류마티스제제(DMARDs), 차세대 표적 치료제는 류마티스 관절염 관리에 있으며, 매우 중요합니다. 이 보고서는 2024-2033년 RA 관리에 있으며, 이들 치료제의 중요한 역할에 대해 자세히 설명하며, 2024-2033년 RA 관리의 동향, 규제 영향 및 발전에 초점을 맞추었습니다.

시장 성장 촉진요인:

류마티스 관절염 치료 시장의 성장을 가속하는 몇 가지 요인이 있습니다. 류마티스 관절염의 전 세계 유병률 증가는 주요 촉진요인이며, RA에 취약한 노인 인구 증가도 마찬가지입니다. 생물학적 제제 및 바이오시밀러의 발전은 효능과 안전성 프로파일을 개선하여 RA 관리를 변화시켰습니다. 또한 의료비 지출 증가, 진단 기술 향상, RA 조기 진단 및 치료에 대한 인식이 높아지면서 시장 확대에 기여하고 있습니다.

시장 성장 억제요인 :

긍정적인 성장 전망에도 불구하고 RA 치료 시장은 문제에 직면해 있습니다. 생물학적 제제는 고가이기 때문에 특히 개발도상국에서는 환자 접근성이 제한될 수 있습니다. 또한 부작용의 가능성과 새로운 치료법의 장기적인 안전성 프로파일은 환자의 순응도에 영향을 미치는 우려 사항입니다. 또한 생물학적 제제 및 바이오시밀러에 대한 복잡한 규제 환경은 시장 진입을 방해하고 신약 승인 절차를 지연시킬 수 있습니다.

시장 기회 :

RA 치료 시장에는 몇 가지 성장과 혁신의 기회가 있습니다. 바이오시밀러의 개발은 생물학적 제제에 대한 비용 효율적인 대안을 제공하고 치료 접근성을 높일 수 있습니다. 개인 맞춤형 치료와 환자 개인별 프로파일에 맞춘 정밀 치료의 발전은 치료 결과를 개선할 수 있는 잠재력을 가지고 있으며, RA 유병률이 증가하고 의료 인프라가 구축되고 있는 신흥 국가 시장 개척은 큰 성장 기회로 작용할 것입니다. 또한 새로운 치료 표적과 병용요법에 대한 지속적인 연구로 보다 효과적인 RA 관리가 가능해질 것으로 기대됩니다.

서론/주요 조사 결과
과거 시장 규모(금액)의 분석, 2019-2023년
현재 및 향후 시장 규모(금액)의 분석과 예측, 2024-2033년
- 대증요법
- 중등도 코르티코스테로이드 요법
- 줄기세포 요법
- 질환 조절 항류마티스약(DMARD)
  - 기존 DMARD
  - 생물학적 DMARD
요법별 시장의 매력 분석

제9장 세계의 류마티스 관절염 치료 시장 분석 : 유통 채널별

서론/주요 조사 결과
과거 시장 규모(금액)의 분석, 2019-2023년
현재 및 향후 시장 규모(금액)의 분석과 예측, 2024-2033년
- 병원 약국
- 소매 약국
- 드러그스토어
유통 채널별 시장의 매력 분석

제10장 세계의 류마티스 관절염 치료 시장 분석 : 지역별

서론
과거 시장 규모(금액)의 분석, 2019-2023년
현재 및 향후 시장 규모(금액)의 분석과 예측, 2024-2033년
- 북미
- 라틴아메리카
- 유럽
- 동아시아
- 남아시아
- 오세아니아
- 중동 및 아프리카(중동 및 아프리카)
지역별 시장의 매력 분석

제11장 북미의 류마티스 관절염 치료 시장 분석

제12장 라틴아메리카의 류마티스 관절염 치료 시장 분석

제13장 유럽의 류마티스 관절염 치료 시장 분석

제14장 동아시아의 류마티스 관절염 치료 시장 분석

제15장 남아시아의 류마티스 관절염 치료 시장 분석

제16장 오세아니아의 류마티스 관절염 치료 시장

제17장 중동 및 아프리카의 류마티스 관절염 치료 시장 분석

제18장 시장 구조 분석

기업 계층별 시장 분석
주요 기업의 시장 점유율 분석
시장 입지 분석

제19장 경쟁 분석

경쟁 대시보드
경쟁의 상세
- Sanofi SA
- Pfizer Inc.
- Johnson &Johnson
- AbbVie Inc.
- Eli Lilly &Company
- Amgen Inc.
- Bristol-Myers Squibb Company
- F. Hoffman-La Roche AG
- Cipla, Inc.
- Sun Pharmaceutical Industries Ltd.
- Sobi Inc.
- Novartis AG(Sandoz)
- UCB SA.

제20장 사용되는 전제 조건과 두자어

제21장 조사 방법

KSA

영문 목차

영문목차

Persistence Market Research provides an in-depth analysis of the global Rheumatoid Arthritis (RA) Treatment Market, highlighting market dynamics, growth drivers, challenges, and emerging trends. This report is a valuable resource for stakeholders, offering comprehensive data and insights for navigating the market landscape from 2024 to 2033.

The global rheumatoid arthritis treatment market is projected to grow significantly between 2024 and 2033, with an expected CAGR of 5.8% during this period. The market is estimated to increase from a value of USD 47.5 billion in 2024 to USD 79.1 billion by the end of 2033.

Key Insights:

Estimated Market Value (2024): USD 47.5 Billion
Projected Market Value (2033): USD 79.1 Billion
Global Market Growth Rate (CAGR 2024 to 2033): 5.8%

Rheumatoid Arthritis Treatment Market - Report Scope:

Rheumatoid arthritis is a chronic inflammatory disorder affecting joints, leading to painful swelling and potential joint deformity. The growing prevalence of RA, coupled with increasing awareness and advancements in treatment options, drives the market. Biologic drugs, Disease-Modifying Anti-Rheumatic Drugs (DMARDs), and new-generation targeted therapies are pivotal in managing RA. The report details the significant role of these treatments, highlighting trends, regulatory impacts, and advancements in RA management from 2024 to 2033.

Market Growth Drivers:

Several factors drive the growth of the RA treatment market. The increasing prevalence of rheumatoid arthritis globally is a primary driver, as is the rising geriatric population, which is more susceptible to RA. Advancements in biologic and biosimilar drugs have transformed RA management, offering improved efficacy and safety profiles. Additionally, increased healthcare spending, improved diagnostic techniques, and growing awareness about early RA diagnosis and treatment contribute to market expansion.

Market Restraints:

Despite its positive growth outlook, the RA treatment market faces challenges. The high cost of biologic therapies can limit accessibility for patients, especially in developing regions. Potential side effects and the long-term safety profile of new treatments are also concerns that can affect patient compliance. Moreover, the complex regulatory landscape for biologics and biosimilars can hinder market entry and slow down the approval process for new drugs.

Market Opportunities:

The RA treatment market offers several opportunities for growth and innovation. The development of biosimilars provides a cost-effective alternative to biologics, increasing treatment accessibility. Personalized medicine and advancements in precision therapies tailored to individual patient profiles are gaining traction, potentially improving treatment outcomes. Expanding markets in developing regions, where RA prevalence is rising and healthcare infrastructure is improving, present significant growth opportunities. Additionally, continued research into novel therapeutic targets and combination therapies holds promise for more effective RA management.

Competitive Landscape and Business Strategies:

Leading companies in the RA treatment market include AbbVie Inc., Amgen Inc., and Pfizer Inc. These companies focus on research and development to introduce innovative therapies and improve existing treatments. Strategic collaborations, mergers, and acquisitions are common strategies to enhance market presence and expand product portfolios. For instance, AbbVie's Humira and Pfizer's Xeljanz are well-known RA treatments that contribute significantly to their respective market shares.

Companies are also investing in patient support programs and educational initiatives to improve treatment adherence and outcomes. Expanding distribution networks and leveraging digital platforms for patient engagement are additional strategies employed by key players to sustain growth and maintain a competitive edge.

Key Companies Profiled:

AbbVie Inc.
Amgen Inc.
Pfizer Inc.
Johnson & Johnson
Bristol-Myers Squibb Company
Novartis AG
Roche Holding AG
UCB S.A.
Eli Lilly and Company
Sanofi S.A.

Rheumatoid Arthritis Treatment Market Segmentation:

Therapy:

Symptomatic Treatment
Intermediate Corticosteroid Therapies
Stem Cell Therapy
Disease Modifying Anti-rheumatic Drug (DMARD)

Conventional DMARDs

Biologic DMARDs

Distribution Channel:

Hospital Pharmacy
Retail Pharmacy
Drug Stores

Region:

North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa

1. Executive Summary

1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market
3.2. Market Innovation / Development Trends

4. Key Success Factors

4.1. Therapy Adoption Analysis
4.2. Patient Treatment Regime
4.3. Key Regulations
4.4. PESTEL Analysis
4.5. Key Promotional Strategies, By Key Players

5. Market Background

5.1. Macro-Economic Factors
- 5.1.1. Global GDP Growth Outlook
- 5.1.2. Global Healthcare Outlook
5.2. Forecast Factors - Relevance & Impact
- 5.2.1. Increase in R&D Spending
- 5.2.2. Growing Lifestyle Disease Prevalence
- 5.2.3. Cost of Therapy
- 5.2.4. Strategic Collaborations
- 5.2.5. Changes in Regulatory Policies
5.3. Market Dynamics
- 5.3.1. Drivers
- 5.3.2. Restraints
- 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

6.1. COVID-19 and Impact Analysis
- 6.1.1. By Therapy
- 6.1.2. By Distribution Channel
- 6.1.3. By Country
6.2. 2024 Market Scenario

7. Global Rheumatoid Arthritis Treatment Market Demand (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033

7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
- 7.2.1. Y-o-Y Growth Trend Analysis
- 7.2.2. Absolute $ Opportunity Analysis

8. Global Rheumatoid Arthritis Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Therapy

8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Bn) Analysis By Therapy, 2019-2023
8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Therapy, 2024-2033
- 8.3.1. Symptomatic Treatment
- 8.3.2. Intermediate Corticosteroid Therapies
- 8.3.3. Stem Cell Therapy
- 8.3.4. Disease Modifying Anti-rheumatic Drug (DMARD)
  - 8.3.4.1. Conventional DMARDs
  - 8.3.4.2. Biologic DMARDs
8.4. Market Attractiveness Analysis By Therapy

9. Global Rheumatoid Arthritis Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Distribution Channel

9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Bn) Analysis, By Distribution Channel, 2019-2023
9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Distribution Channel, 2024-2033
- 9.3.1. Hospital Pharmacy
- 9.3.2. Retail Pharmacy
- 9.3.3. Drug Stores
9.4. Market Attractiveness Analysis By Distribution Channel

10. Global Rheumatoid Arthritis Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Region

10.1. Introduction
10.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
10.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, 2024-2033
- 10.3.1. North America
- 10.3.2. Latin America
- 10.3.3. Europe
- 10.3.4. East Asia
- 10.3.5. South Asia
- 10.3.6. Oceania
- 10.3.7. Middle East and Africa (MEA)
10.4. Market Attractiveness Analysis By Region

11. North America Rheumatoid Arthritis Treatment Market Analysis 2019-2023 and Forecast 2024-2033

11.1. Introduction
11.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
11.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
- 11.3.1. By Country
  - 11.3.1.1. U.S.
  - 11.3.1.2. Canada
- 11.3.2. By Therapy
- 11.3.3. By Distribution Channel
11.4. Market Attractiveness Analysis
- 11.4.1. By Country
- 11.4.2. By Therapy
- 11.4.3. By Distribution Channel
11.5. Market Trends
11.6. Drivers and Restraints - Impact Analysis
11.7. Key Players - Intensity Mapping
11.8. Country Level Analysis & Forecast
- 11.8.1. U.S. Rheumatoid Arthritis Treatment Market Analysis
  - 11.8.1.1. Introduction
  - 11.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 11.8.1.2.1. By Therapy
    - 11.8.1.2.2. By Distribution Channel
- 11.8.2. Canada Rheumatoid Arthritis Treatment Market Analysis
  - 11.8.2.1. Introduction
  - 11.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 11.8.2.2.1. By Therapy
    - 11.8.2.2.2. By Distribution Channel

12. Latin America Rheumatoid Arthritis Treatment Market Analysis 2019-2023 and Forecast 2024-2033

12.1. Introduction
12.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
12.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
- 12.3.1. By Country
  - 12.3.1.1. Mexico
  - 12.3.1.2. Brazil
  - 12.3.1.3. Argentina
  - 12.3.1.4. Rest of Latin America
- 12.3.2. By Therapy
- 12.3.3. By Distribution Channel
12.4. Market Attractiveness Analysis
- 12.4.1. By Country
- 12.4.2. By Therapy
- 12.4.3. By Distribution Channel
12.5. Market Trends
12.6. Drivers and Restraints - Impact Analysis
12.7. Key Players - Intensity Mapping
12.8. Country Level Analysis & Forecast
- 12.8.1. Mexico Rheumatoid Arthritis Treatment Market Analysis
  - 12.8.1.1. Introduction
  - 12.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 12.8.1.2.1. By Therapy
    - 12.8.1.2.2. By Distribution Channel
- 12.8.2. Brazil Rheumatoid Arthritis Treatment Market Analysis
  - 12.8.2.1. Introduction
  - 12.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 12.8.2.2.1. By Therapy
    - 12.8.2.2.2. By Distribution Channel
- 12.8.3. Argentina Rheumatoid Arthritis Treatment Market Analysis
  - 12.8.3.1. Introduction
  - 12.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 12.8.3.2.1. By Therapy
    - 12.8.3.2.2. By Distribution Channel

13. Europe Rheumatoid Arthritis Treatment Market Analysis 2019-2023 and Forecast 2024-2033

13.1. Introduction
13.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
13.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
- 13.3.1. By Country
  - 13.3.1.1. Germany
  - 13.3.1.2. Italy
  - 13.3.1.3. France
  - 13.3.1.4. U.K.
  - 13.3.1.5. Spain
  - 13.3.1.6. BENELUX
  - 13.3.1.7. Russia
  - 13.3.1.8. Rest of Europe
- 13.3.2. By Therapy
- 13.3.3. By Distribution Channel
13.4. Market Attractiveness Analysis
- 13.4.1. By Country
- 13.4.2. By Therapy
- 13.4.3. By Distribution Channel
13.5. Market Trends
13.6. Drivers and Restraints - Impact Analysis
13.7. Key Players - Intensity Mapping
13.8. Country Level Analysis & Forecast
- 13.8.1. Germany Rheumatoid Arthritis Treatment Market Analysis
  - 13.8.1.1. Introduction
  - 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.1.2.1. By Therapy
    - 13.8.1.2.2. By Distribution Channel
- 13.8.2. Italy Rheumatoid Arthritis Treatment Market Analysis
  - 13.8.2.1. Introduction
  - 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.2.2.1. By Therapy
    - 13.8.2.2.2. By Distribution Channel
- 13.8.3. France Rheumatoid Arthritis Treatment Market Analysis
  - 13.8.3.1. Introduction
  - 13.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.3.2.1. By Therapy
    - 13.8.3.2.2. By Distribution Channel
- 13.8.4. U.K. Rheumatoid Arthritis Treatment Market Analysis
  - 13.8.4.1. Introduction
  - 13.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.4.2.1. By Therapy
    - 13.8.4.2.2. By Distribution Channel
- 13.8.5. Spain Rheumatoid Arthritis Treatment Market Analysis
  - 13.8.5.1. Introduction
  - 13.8.5.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.5.2.1. By Therapy
    - 13.8.5.2.2. By Distribution Channel
- 13.8.6. BENELUX Rheumatoid Arthritis Treatment Market Analysis
  - 13.8.6.1. Introduction
  - 13.8.6.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.6.2.1. By Therapy
    - 13.8.6.2.2. By Distribution Channel
- 13.8.7. Russia Rheumatoid Arthritis Treatment Market Analysis
  - 13.8.7.1. Introduction
  - 13.8.7.2. Market Analysis and Forecast by Market Taxonomy
    - 13.8.7.2.1. By Therapy
    - 13.8.7.2.2. By Distribution Channel

14. East Asia Rheumatoid Arthritis Treatment Market Analysis 2019-2023 and Forecast 2024-2033

14.1. Introduction
14.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
14.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
- 14.3.1. By Country
  - 14.3.1.1. China
  - 14.3.1.2. Japan
  - 14.3.1.3. South Korea
- 14.3.2. By Therapy
- 14.3.3. By Distribution Channel
14.4. Market Attractiveness Analysis
- 14.4.1. By Country
- 14.4.2. By Therapy
- 14.4.3. By Distribution Channel
14.5. Market Trends
14.6. Drivers and Restraints - Impact Analysis
14.7. Key Players - Intensity Mapping
14.8. Country Level Analysis & Forecast
- 14.8.1. China Rheumatoid Arthritis Treatment Market Analysis
  - 14.8.1.1. Introduction
  - 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.1.2.1. By Therapy
    - 14.8.1.2.2. By Distribution Channel
- 14.8.2. Japan Rheumatoid Arthritis Treatment Market Analysis
  - 14.8.2.1. Introduction
  - 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.2.2.1. By Therapy
    - 14.8.2.2.2. By Distribution Channel
- 14.8.3. South Korea Rheumatoid Arthritis Treatment Market Analysis
  - 14.8.3.1. Introduction
  - 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 14.8.3.2.1. By Therapy
    - 14.8.3.2.2. By Distribution Channel

15. South Asia Rheumatoid Arthritis Treatment Market Analysis 2019-2023 and Forecast 2024-2033

15.1. Introduction
15.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
15.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
- 15.3.1. By Country
  - 15.3.1.1. India
  - 15.3.1.2. Indonesia
  - 15.3.1.3. Malaysia
  - 15.3.1.4. Thailand
  - 15.3.1.5. Rest of South Asia
- 15.3.2. By Therapy
- 15.3.3. By Distribution Channel
15.4. Market Attractiveness Analysis
- 15.4.1. By Country
- 15.4.2. By Therapy
- 15.4.3. By Distribution Channel
15.5. Market Trends
15.6. Drivers and Restraints - Impact Analysis
15.7. Key Players - Intensity Mapping
15.8. Country Level Analysis & Forecast
- 15.8.1. India Rheumatoid Arthritis Treatment Market Analysis
  - 15.8.1.1. Introduction
  - 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.1.2.1. By Therapy
    - 15.8.1.2.2. By Distribution Channel
- 15.8.2. Indonesia Rheumatoid Arthritis Treatment Market Analysis
  - 15.8.2.1. Introduction
  - 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.2.2.1. By Therapy
    - 15.8.2.2.2. By Distribution Channel
- 15.8.3. Malaysia Rheumatoid Arthritis Treatment Market Analysis
  - 15.8.3.1. Introduction
  - 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.3.2.1. By Therapy
    - 15.8.3.2.2. By Distribution Channel
- 15.8.4. Thailand Rheumatoid Arthritis Treatment Market Analysis
  - 15.8.4.1. Introduction
  - 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 15.8.4.2.1. By Therapy
    - 15.8.4.2.2. By Distribution Channel

16. Oceania Rheumatoid Arthritis Treatment Market 2019-2023 and Forecast 2024-2033

16.1. Introduction
16.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
16.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
- 16.3.1. By Country
  - 16.3.1.1. Australia
  - 16.3.1.2. New Zealand
- 16.3.2. By Therapy
- 16.3.3. By Distribution Channel
16.4. Market Attractiveness Analysis
- 16.4.1. By Country
- 16.4.2. By Therapy
- 16.4.3. By Distribution Channel
16.5. Market Trends
16.6. Drivers and Restraints - Impact Analysis
16.7. Key Players - Intensity Mapping
16.8. Country Level Analysis & Forecast
- 16.8.1. Australia Rheumatoid Arthritis Treatment Market Analysis
  - 16.8.1.1. Introduction
  - 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.1.2.1. By Therapy
    - 16.8.1.2.2. By Distribution Channel
- 16.8.2. New Zealand Rheumatoid Arthritis Treatment Market Analysis
  - 16.8.2.1. Introduction
  - 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 16.8.2.2.1. By Therapy
    - 16.8.2.2.2. By Distribution Channel

17. Middle East and Africa (MEA) Rheumatoid Arthritis Treatment Market Analysis 2019-2023 and Forecast 2024-2033

17.1. Introduction
17.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
17.3. Current and Future Market Value (US$ Bn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
- 17.3.1. By Country
  - 17.3.1.1. GCC Countries
  - 17.3.1.2. Turkey
  - 17.3.1.3. North Africa
  - 17.3.1.4. South Africa
  - 17.3.1.5. Rest of Middle East and Africa
- 17.3.2. By Therapy
- 17.3.3. By Distribution Channel
17.4. Market Attractiveness Analysis
- 17.4.1. By Country
- 17.4.2. By Therapy
- 17.4.3. By Distribution Channel
17.5. Market Trends
17.6. Drivers and Restraints - Impact Analysis
17.7. Key Players - Intensity Mapping
17.8. Country Level Analysis & Forecast
- 17.8.1. GCC Countries Rheumatoid Arthritis Treatment Market Analysis
  - 17.8.1.1. Introduction
  - 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.1.2.1. By Therapy
    - 17.8.1.2.2. By Distribution Channel
- 17.8.2. Turkey Rheumatoid Arthritis Treatment Market Analysis
  - 17.8.2.1. Introduction
  - 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.2.2.1. By Therapy
    - 17.8.2.2.2. By Distribution Channel
- 17.8.3. South Africa Rheumatoid Arthritis Treatment Market Analysis
  - 17.8.3.1. Introduction
  - 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.3.2.1. By Therapy
    - 17.8.3.2.2. By Distribution Channel
- 17.8.4. North Africa Rheumatoid Arthritis Treatment Market Analysis
  - 17.8.4.1. Introduction
  - 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
    - 17.8.4.2.1. By Therapy
    - 17.8.4.2.2. By Distribution Channel

18. Market Structure Analysis

18.1. Market Analysis by Tier of Companies
18.2. Market Share Analysis of Top Players
18.3. Market Presence Analysis

19. Competition Analysis

19.1. Competition Dashboard
19.2. Competition Deep Dive
- 19.2.1. Sanofi S.A.
  - 19.2.1.1. Overview
  - 19.2.1.2. Product Portfolio
  - 19.2.1.3. Sales Footprint
  - 19.2.1.4. Key Financials
  - 19.2.1.5. SWOT Analysis
  - 19.2.1.6. Strategy Overview
    - 19.2.1.6.1. Marketing Strategy
    - 19.2.1.6.2. Channel Strategy
- 19.2.2. Pfizer Inc.
  - 19.2.2.1. Overview
  - 19.2.2.2. Product Portfolio
  - 19.2.2.3. Sales Footprint
  - 19.2.2.4. Key Financials
  - 19.2.2.5. SWOT Analysis
  - 19.2.2.6. Strategy Overview
    - 19.2.2.6.1. Marketing Strategy
    - 19.2.2.6.2. Channel Strategy
- 19.2.3. Johnson & Johnson
  - 19.2.3.1. Overview
  - 19.2.3.2. Product Portfolio
  - 19.2.3.3. Sales Footprint
  - 19.2.3.4. Key Financials
  - 19.2.3.5. SWOT Analysis
  - 19.2.3.6. Strategy Overview
    - 19.2.3.6.1. Marketing Strategy
    - 19.2.3.6.2. Channel Strategy
- 19.2.4. AbbVie Inc.
  - 19.2.4.1. Overview
  - 19.2.4.2. Product Portfolio
  - 19.2.4.3. Sales Footprint
  - 19.2.4.4. Key Financials
  - 19.2.4.5. SWOT Analysis
  - 19.2.4.6. Strategy Overview
    - 19.2.4.6.1. Marketing Strategy
    - 19.2.4.6.2. Channel Strategy
- 19.2.5. Eli Lilly & Company
  - 19.2.5.1. Overview
  - 19.2.5.2. Product Portfolio
  - 19.2.5.3. Sales Footprint
  - 19.2.5.4. Key Financials
  - 19.2.5.5. SWOT Analysis
  - 19.2.5.6. Strategy Overview
    - 19.2.5.6.1. Marketing Strategy
    - 19.2.5.6.2. Channel Strategy
- 19.2.6. Amgen Inc.
  - 19.2.6.1. Overview
  - 19.2.6.2. Product Portfolio
  - 19.2.6.3. Sales Footprint
  - 19.2.6.4. Key Financials
  - 19.2.6.5. SWOT Analysis
  - 19.2.6.6. Strategy Overview
    - 19.2.6.6.1. Marketing Strategy
    - 19.2.6.6.2. Channel Strategy
- 19.2.7. Bristol-Myers Squibb Company
  - 19.2.7.1. Overview
  - 19.2.7.2. Product Portfolio
  - 19.2.7.3. Sales Footprint
  - 19.2.7.4. Key Financials
  - 19.2.7.5. SWOT Analysis
  - 19.2.7.6. Strategy Overview
    - 19.2.7.6.1. Marketing Strategy
    - 19.2.7.6.2. Channel Strategy
- 19.2.8. F. Hoffman-La Roche AG
  - 19.2.8.1. Overview
  - 19.2.8.2. Product Portfolio
  - 19.2.8.3. Sales Footprint
  - 19.2.8.4. Key Financials
  - 19.2.8.5. SWOT Analysis
  - 19.2.8.6. Strategy Overview
    - 19.2.8.6.1. Marketing Strategy
    - 19.2.8.6.2. Channel Strategy
- 19.2.9. Cipla, Inc.
  - 19.2.9.1. Overview
  - 19.2.9.2. Product Portfolio
  - 19.2.9.3. Sales Footprint
  - 19.2.9.4. Key Financials
  - 19.2.9.5. SWOT Analysis
  - 19.2.9.6. Strategy Overview
    - 19.2.9.6.1. Marketing Strategy
    - 19.2.9.6.2. Channel Strategy
- 19.2.10. Sun Pharmaceutical Industries Ltd.
  - 19.2.10.1. Overview
  - 19.2.10.2. Product Portfolio
  - 19.2.10.3. Sales Footprint
  - 19.2.10.4. Key Financials
  - 19.2.10.5. SWOT Analysis
  - 19.2.10.6. Strategy Overview
    - 19.2.10.6.1. Marketing Strategy
    - 19.2.10.6.2. Channel Strategy
- 19.2.11. Sobi Inc.
  - 19.2.11.1. Overview
  - 19.2.11.2. Product Portfolio
  - 19.2.11.3. Sales Footprint
  - 19.2.11.4. Key Financials
  - 19.2.11.5. SWOT Analysis
  - 19.2.11.6. Strategy Overview
    - 19.2.11.6.1. Marketing Strategy
    - 19.2.11.6.2. Channel Strategy
- 19.2.12. Novartis AG ( Sandoz)
  - 19.2.12.1. Overview
  - 19.2.12.2. Product Portfolio
  - 19.2.12.3. Sales Footprint
  - 19.2.12.4. Key Financials
  - 19.2.12.5. SWOT Analysis
  - 19.2.12.6. Strategy Overview
    - 19.2.12.6.1. Marketing Strategy
    - 19.2.12.6.2. Channel Strategy
- 19.2.13. UCB S.A..
  - 19.2.13.1. Overview
  - 19.2.13.2. Product Portfolio
  - 19.2.13.3. Sales Footprint
  - 19.2.13.4. Key Financials
  - 19.2.13.5. SWOT Analysis
  - 19.2.13.6. Strategy Overview
    - 19.2.13.6.1. Marketing Strategy
    - 19.2.13.6.2. Channel Strategy